Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07609914 · ClinicalTrials.gov registry record · Phase 4
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
A Phase 4 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
NCT07609914 is a Phase 4 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 400 participants.
The verdict
NCT07609914, a Phase 4 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
Study Summary
Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack. The primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.
Interventions
- DRUG Rimegepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2028-05-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07609914
The ClinicalTrials.gov registry entry for NCT07609914 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rimegepant is the first listed.
NCT07609914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07609914 about?
NCT07609914 is a clinical study titled "A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine". Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose o...
What is the current status of trial NCT07609914?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2026-05-28. Estimated completion is 2028-05-15.
What interventions are being tested in trial NCT07609914?
The interventions under investigation include: Rimegepant (DRUG).
Who is sponsoring clinical trial NCT07609914?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.